Subject: Brandon Did This
Sanofi joins Eli Lilly and Novo Nordisk -- the three pharmaceutical companies that make up about 90% of the insulin market in the U.S. -- and announces price cuts or out-of-pocket caps.

Sanofi will cap the out-of-pocket cost of its most popular insulin, Lantus, at $35 per month for people with private insurance, the French drugmaker said Thursday. The change will take effect Jan. 1, 2024.

Sanofi is the last of three major insulin makers in the United States to cut or cap the price of the drug.

Had Trump been able to pull this off, he would have demanded a ticker-tape parade in every major city in America and awarded himself the Congressional Medal of Honor.

https://www.nbcnews.com/health...